RxDoctor Payments Data

Stephanie Coleman

Nurse Practitioner · Little Rock, ARNPI 1073025623

Payments from drug & device makers

$2,659in general payments, 2019–2025

Across 92 payments — averaging $28.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$707
  • Novartis$346
  • Sanofi-aventis U.S. LLC$290
  • AstraZeneca$274
  • Irhythm Technologies, Inc.$160
  • Abbott$153
  • plus $730 from 12 others

What the payments were for

  • Food & beverage$2,61498%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,659 in reported general payments places this provider in the 85th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$49,115
Medicare patients
560
Services billed
873

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$93,596
EntrestoSacubitril/Valsartan58$47,456
FarxigaDapagliflozin Propanediol40$30,368
XareltoRivaroxaban32$22,428
MultaqDronedarone Hcl14$17,351
Metoprolol Succinate440$8,036
Dofetilide36$2,902
Mexiletine Hcl25$1,719
Nebivolol Hcl18$1,406
Propafenone Hcl16$1,017
Potassium Chloride73$780
SotalolSotalol Hcl31$666
Midodrine Hcl11$595
Carvedilol68$589
Amiodarone Hcl50$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$77$93,596116 claims
NovartisEntresto$346$47,45658 claims
AstraZenecaFarxiga$274$30,36840 claims
Johnson & JohnsonXarelto$115$22,42832 claims
Sanofi-aventis U.S. LLCMultaq$290$17,35114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →